



The endogenous neurosteroid system and its role in the pathogenesis and therapy of mental disorders

Takeena P. Bairamova¹, Dmitry S. Petelin², Roman V. Akhapiin¹, Nikita V. Kudryashov², Olga Yu. Sorokina², Sergey A. Semin³, Veronika Panfilova², Beatrice A. Volel²

1 *Serbsky National Medical Research Center of Psychiatry and Narcology, 23 Kropotkinsky Lane, Moscow 119034 Russia*

2 *Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 2-4 Bolshaya Pirogovskaya St., Moscow 119991 Russia*

3 *"Spaseniye" Psychiatric Hospital, 9/2 Plekhanova St., Moscow 111141 Russia*

Corresponding author: Takeena P. Bairamova (bairamova23s@gmail.com)

Academic editor: Oleg Gudyrev ♦ Received 10 October 2022 ♦ Accepted 03 March 2023 ♦ Published 31 March 2023

Citation: Bairamova SP, Petelin DS, Akhapiin RV, Kudryashov NV, Sorokina OYu, Semin SA, Panfilova V, Volel BA (2023) The endogenous neurosteroid system and its role in the pathogenesis and therapy of mental disorders. *Research Results in Pharmacology* 9(1): 61–69. <https://doi.org/10.18413/rrpharmacology.9.10015>

Abstract


Introduction: Although neurosteroids have been relatively recently discovered, their significant role in the neurochemical processes and pathogenesis of a number of psychiatric and neurological disorders is now quite clear. First of all, it seems important to clarify the definition of the endogenous neurosteroids as a class of steroids, taking into account the variability of approaches to their description. Currently, neurosteroids include endogenous steroids synthesized in the central nervous system, gonads, or adrenal glands and interacting with GABA_A, NMDA, and sigma-1 receptors.

Neurosteroid biosynthesis: Biosynthesis of neurosteroids begins with rate-limiting reaction of **TSPO** binding **cholesterol** and transporting it into the mitochondria, where **pregnenolone** is synthesized following the cytochrome P450scc (CYP11A1) impact.

Interaction with GABA_A, NMDA and sigma-1 receptors: According to the experimental data, neurosteroids act as the most highly potent endogenous allosteric modulators of the GABA receptor; some types of neurosteroids (**ALLO**, **DHEA**, etc.) can produce a rapid anxiolytic and anticonvulsant effect. There is some experimental evidence for antipsychotic effects of some neurosteroids realized through NMDA receptors: intracerebral administration of **ALLO** to laboratory animals can prevent further appearance of motor agitation and other equivalents of psychosis after administration of high doses of amphetamines. It has also been proven in several studies on animal models that neurosteroids exhibit anxiolytic effects through sigma-1 receptors.

Conclusion: The article describes the process of neurosteroidogenesis and the effect of neurosteroids on listed receptors in accordance with already available scientific data. In addition, this paper describes the specific role of various neurosteroids in the development of mental illnesses, including anxiety disorders, depression, and schizophrenia

Graphical Abstract



Keywords

allopregnanolone, GABA_A-receptors, DHEA, NMDA-receptors, pregnenolone, sigma-1 receptors, steroidogenesis, TSPO.

Introduction

About 40 years ago, the long-term presence of steroid hormones in the brain of rodents after adrenalectomy and castration was first discovered. In 1981, Corpéchet et al. (1981) demonstrated that some steroids are synthesized directly in the brain. Subsequently, in 1992, Paul and Purdy coined the term "neuroactive steroids" to include all natural or synthetic steroids that affect neuronal excitability via non-genomic mechanisms. The term was accepted in the literature, but Baulieu transformed the term which implied steroids with 3 properties: a) they are synthesized within the nervous system *de novo* from cholesterol; b) their presence in the nervous system after removal of steroidogenic tissues was demonstrated; c) the enzymes involved in their synthesis are expressed within the nervous system (NS) (Schumacher et al. 2009). Later, the original term included steroids synthesized within the NS, but from peripheral metabolic precursors. Currently, neurosteroids include endogenous steroids synthesized in the central nervous system (CNS), gonads, or adrenal glands and interacting with GABA_A, NMDA, and sigma-1 receptors. This term most often refers to 3 α -

hydroxy metabolites of progesterone, deoxycorticosterone and testosterone with a reduced A-aromatic ring, GABA_A receptor agonists, and 3 β -hydroxy pregnane with a reduced A-aromatic ring, GABA_A receptor antagonists (Compagnone and Mellon 2000).

Neurosteroids biosynthesis

The CNS steroids can be conditionally classified into two types:

1. Neuroactive steroids which are synthesized in adrenal glands, gonads or placenta (i.e., in the peripheral steroid organs) and which penetrated blood-brain barrier;

2. Neurosteroids which are synthesized within the CNS *de novo* from cholesterol or *in situ* from steroid metabolic precursors circulating in the blood (Do Rego et al. 2012).

The vast majority of steroids, except for conjugated ones, easily pass through the blood-brain barrier by diffusion or via transport proteins, such as organic anion transporting polypeptides or monocarboxylate transporters (Schumacher et al. 2009; Banks 2012; Witt

et al. 2014). Steroid hormones from peripheral organs are transported to the brain in a complex with albumin, transcortin, and sex hormone-binding globulin (Dietel et al. 2018). It is important to understand in which structures of the NS and by what types of cells neurosteroids are synthesized, but this depends on a number of factors. For example, in the brain of adult rats, aromatase, which is involved in the transformation of androgens into estrogens, is expressed exclusively by neurons. However, in the case of excitotoxicity or injury, it can also be expressed by astrocytes, which can be considered as indirect evidence of the neuroprotective effect of some neurosteroids (Schumacher et al. 2009). It is possible to determine the origin of the steroid using the enzymes involved in its synthesis, since the expression and activity of the enzyme in certain areas indicate the corresponding metabolic pathways. Cytochrome P450_{scc} activity was found in the spinal ganglia, dorsal horns of the spinal cord, and somatosensory cortex, indicating a broad area of expression (Schumacher et al. 2009). The literature data suggests that neurosteroids are synthesized both in the CNS and in the peripheral NS. The experiments with cell cultures demonstrated that the neuroactive progesterone metabolite **allopregnanolone** is synthesized mainly by glial cells and interacts with GABA_A-receptors of nearby neurons (paracrine). These data agree with the results of the *in vivo* studies: the activity of the enzyme 3 α -hydroxysteroid dehydrogenase (3 α -HSD) in the olfactory bulbs of rats did not change after the administration of kainic acid, which destroys neurons, but does not damage glial cells (Schumacher et al. 2009). *De novo* synthesis from **cholesterol** in glial cells and the CNS neurons takes place predominantly in the hypothalamus and limbic structures (hippocampus, amygdala) (Kalinina et al. 2014). However, such a generalization of localizations can be found mainly in the works of the Russian authors.

The first step in steroidogenesis in any tissue is **cholesterol** transport into the mitochondria. **Cholesterol** is transported to the outer mitochondrial membrane mainly in 2 ways: via facilitated diffusion with soluble lipid transfer proteins or via diffusion across membrane contact sites (Elustondo et al. 2017). The data of molecular models and spectroscopic analysis demonstrated that the proteins involved in the **cholesterol** transport to the outer membrane are the proteins containing the START-domain (StAR-related lipid-transfer), presumably STARD1, STARD3 and STARD4 (Calderon-Dominguez et al. 2014; Elustondo et al. 2017), and oxysterol-binding proteins. However, there are many more mechanisms involved in this process, and this is an open field for study. The **cholesterol** transport from the outer to the inner mitochondrial membrane is an important rate-limiting step in steroidogenesis. Despite its importance, its mechanism is not completely clear. Presumably, it involves the 800kD multiprotein complex, which includes the **translocation protein (TSPO)**, voltage-

dependent anion channel (VDAC), P450_{scc} cytochrome, ATP-binding domain AAA, and optic nerve atrophy protein 1 (McNeela et al. 2018). The other authors believe that StAR (Steroidogenic Acute Regulatory Protein)/STARD1, auxiliary proteins VDAC and adenine nucleotide translocator play the main role in the **cholesterol** transport to the inner membrane of mitochondria (Rodriguez-Agudo et al. 2006; Kraemer et al. 2017; Larsen et al. 2020). However, **TSPO** also forms protein complexes with them. Monomeric forms of **TSPO** were found on the outer membrane of mitochondria. Apparently, the monomeric **TSPO** binds **cholesterol**, and the protein polymeric forms are involved in **cholesterol** translocation. It is impossible to unambiguously determine the composition of the multiprotein complexes involved in **cholesterol** translocation; however, it is believed that the process of neurosteroid synthesis *per se* begins with the activation of the above-mentioned 18kD mitochondrial translocation protein, **TSPO**, previously referred to as the peripheral benzodiazepine receptor. It binds **cholesterol** and transports it into the mitochondria, where **pregnenolone** is synthesized following the cytochrome P450_{scc} (CYP11A1) impact. This reaction is rate-limiting in the synthesis of neurosteroids. It is noteworthy that diazepam binding inhibitor (peripheral benzodiazepine receptor inhibitory ligand) at nanomolar concentrations stimulates the synthesis of **pregnenolone** from **cholesterol** (Costa et al. 1994). The regulation of steroid synthesis involves follicle-stimulating, luteinizing and adrenocorticotrophic hormones. **TSPO** expression is elevated in degenerative and demyelinating diseases, as well as in response to trauma, suggesting the neuroprotective properties of **TSPO** ligands (Schumacher et al. 2009). Leaving the mitochondria, **pregnenolone** initiates two significant metabolic pathways in neurosteroid synthesis and can develop the sulfated form following sulfotransferase effect. Salman et al. (2011) reported that the SULT2B1b isoform may be the predominant sulfotransferase (SULT) isoform involved in neurosteroid conjugation. However, sulfation of **pregnenolone** to **pregnenolone sulfate** predominantly involves the SULT2B1a enzyme. The SULT1E1 and SULT2A1 isoforms did not participate in neurosteroid sulfation directly in the brain, since expression of these proteins was not revealed by immunohistochemical analysis (Salman et al. 2011). SULT2A1, for example, is involved in **DHEA** sulfation in the reticular zone of the adrenal cortex (Khvostova et al. 2012).

Considering neurosteroidogenesis in detail, it is also important to pay attention to the enzymes involved in biosynthesis (Fig. 1). Following cytochrome P450C17 effect, which acts as 17 α -hydroxylase, 17-OH-pregnenolone is synthesized from **pregnenolone**, then with the same enzyme, but now acting as 17,20-lyase, **DHEA** is synthesized from 17-OH-pregnenolone. **DHEA** can also form the neuroactive sulfated form of

DHEA-S. The reverse reaction is catalyzed by the enzyme sulfatase (STS). The second important cascade of reactions is the synthesis of progesterone and its derivatives. Progesterone is synthesized from **pregnenolone** by the action of 3β -hydroxysteroid dehydrogenase (3β -HSD). Below we will describe the three main reactions, the first of which is the synthesis of **deoxycorticosterone (DOC)** by 21-hydroxylase P450C21. **Deoxycorticosterone** is further transformed into **dihydrodeoxycorticosterone (DHDOC)** by 11β -hydroxylase P450C11, from which **tetrahydrodeoxycorticosterone (THDOC)** can be synthesized. The next important progesterone

derivatives are **5 α -dihydroprogesterone (5 α -DHP)** and **5 β -dihydroprogesterone (5 β -DHP)**, synthesized by 5 α -reductase type 1 and 5 β -reductase type 1, respectively. **5 α -DHP** is transformed into **allopregnanolone (ALLO)** and epi-allopregnanolone (3 β 5 α P). Selective serotonin reuptake inhibitors, such as **fluoxetine**, **sertraline**, **paroxetine**, increase the affinity of 3 α -HSD (type III) for **5 α -DHP** and block the reverse conversion of **ALLO** to **5 α -DHP**, which increases the rate of **allopregnanolone** synthesis (Schumacher et al. 2009). **5 β -DHP** is in turn the precursor of **pregnanolone** and **epipregnanolone**.




Figure 1. Neurosteroidogenesis and the enzyme system involved in the process. **Note:** Neurosteroids: **DHEA** – Dehydroepiandrosterone, **DHEA-S** – Dehydroepiandrosterone sulfate, **DOC** – Deoxycorticosterone, **DHDOC** – Dihydrodeoxycorticosterone, **THDOC** – Tetrahydrodeoxycorticosterone, **5 α -DHP** – 5 α -dihydroprogesterone, **5 β -DHP** – 5 β -dihydroprogesterone, **ALLO** – allopregnanolone, **3 β 5 α P** – epi-allopregnanolone. Enzymes: **TSPO** – Translocator protein, 20,22 Desmolase – P450C11 (CYP11A1), **17 α -hydroxylase** – P450C17 (CYP17A1), **17,20-lyase** – P450C17 (CYP17A1), **SULT** – Sulfatase, **3 β -HSD** – 3 β -hydroxysteroid dehydrogenase, **3 α -HSD** – 3 α -hydroxysteroid dehydrogenase, **21-hydroxylase** – P450C21 (CYP21A2), **5 α -R type 1** – 5 α -Reductase type 1, **5 β -R type 1** – 5 β -Reductase type 1, **11 β -hydroxylase** – P450C11 (CYP11B1).

Interaction with GABA_A, NMDA and sigma-1 receptors

GABA_A receptors are pentameric ligand-gated ion channels consisting of two α -subunits ($\alpha 1-6$), two β -subunits ($\beta 1-3$), and one additional subunit ($\gamma 1-3$, δ , ϵ , π , θ and $\rho 1-3$) (Wang 2011). When ion channels open, the hyperpolarization resulting from the Cl⁻ ions flow leads to inhibition of neuronal activity (Joshi and Kapur 2019). Synaptic GABA_A receptors are located within the synaptic cleft and contain γ -subunits. Often there are receptors with subunit composition: $\alpha 1\beta 2\gamma 2$ (60% of the total), $\alpha 2\beta 3\gamma 2$ (15-20%) and $\alpha 3\beta 2/3\gamma 2$ (10-15%) (Wang 2008). The expression of various GABA_A receptors is specific for different regions of the nervous system. For example, the most common form of $\alpha 1\beta 2\gamma 2$ is found in most regions of the brain: cortex, hippocampus, and Purkinje cells. $\alpha 2\beta 3\gamma 2$ receptors are found in the cortex, hippocampus, amygdala, striatum, and hypothalamus (Wang 2008). Besides the main ligand, gamma-aminobutyric acid, GABA_A receptors can bind many

other compounds, including barbiturates, benzodiazepines, ethanol, zinc, and neurosteroids. It is noteworthy that each type of subunit has specific pharmacological properties and can only interact with certain molecules. The GABA binding sites are between the α and β subunits, and the benzodiazepine site is between the α and γ subunits (Sigel 2002). For neurosteroids, at least three binding sites were found. The receptor activation by neurosteroids, in particular **allopregnanolone**, occurs through a site located between the $\beta 3$ – $\alpha 1$ subunits (Sugasawa et al. 2020). **Allopregnanolone** and epi-allopregnanolone can induce receptor desensitization via sites on the $\beta 3$ subunit, while binding of neurosteroids to the $\alpha 1$ subunit can lead to different effects depending on the molecular structure (Sugasawa et al. 2020). **Allopregnanolone** can potentiate the receptor effect both allosterically (through increased current) and directly, activating the receptor at high concentrations. GABA_A receptor antagonists are **pregnenolone sulfate** and epi-allopregnanolone (Wang 2011).

The nature of the GABA_A receptors interaction is determined not only by the neurosteroid structure and type (agonist/antagonist), but also by the GABA receptor structure (composition of subunits), as well as by the location of the receptor (synaptic and extrasynaptic). Synaptic (phasic) and extrasynaptic (tonic) inhibition are two types of inhibitory neurotransmission mediated through GABA_A receptors. Neurosteroids can potentiate both phasic and tonic currents. The action kinetics of synaptic GABA_A receptor neurosteroid agonists was studied by measuring the spontaneous inhibitory postsynaptic potential (sIPSP) in brain neurons. Neurosteroids may produce a small effect on the time of onset and peak amplitude of sIPSP, reducing the likelihood of a synaptic potential. Agonists prolong the decay time of the impulse. In hippocampal CA1 neurons, granule cells, and Purkinje cells, neurosteroids prolong sIPSP at relatively low (nanomolar) concentrations (Wang 2008). However, at >10 μ M concentrations, neurosteroids can activate GABA_A receptors interacting directly with the binding site (Majewska et al. 1986). This so-called GABA-like effect of neurosteroids is able to suppress excitatory neurotransmission (Shu et al. 2004).

Extrasynaptic GABA_A receptors containing the δ subunit have a very high affinity for some neurosteroids, which may indicate their importance as a target. At concentrations of 10–100 nM, 3 α 5 α -THDOC selectively enhances tonic inhibition (Stell et al. 2003). Tonic inhibition was reduced in δ -subunit knockout mice (Mihalek et al. 1999). However, the extrasynaptic effects of neurosteroids vary in different areas of the CNS. 3 α 5 α -THDOC at 250 nM concentration produced no effect on tonic inhibition in the thalamic ventrobasal complex (Porcello et al. 2003). On the other hand, tonic inhibition of CA1 in hippocampal neurons expressing α 5-subunit GABA_A receptors is affected by 3 α 5 α -THDOC at \geq 100 nM concentrations (Stell et al. 2003). This heterogeneity suggests that potential modulation depends on the specific local metabolism of particular neurosteroids.

According to the experimental data, neurosteroids act as the most highly potent endogenous allosteric modulators of the GABA receptor (Lambert et al. 1995). When administered parenterally, some types of neurosteroids (ALLO, DHEA, etc.) can produce a rapid anxiolytic and anticonvulsant effect, and, with increasing doses, they can also exhibit sedative and hypnotic properties (Longone et al. 2011). According to some data, the neurosteroid system may represent a part of the endogenous anxiolytic system. This point is supported, in particular, by data on a decrease in its activity in patients with panic disorder in whom a panic attack was induced by administration of lactate or cholecystokinin. In turn, administration of placebo to patients or administration of lactate or cholecystokinin to healthy volunteers had no effect on neurosteroid activity. On the other hand, the presence of neurosteroid

effects has also been well documented with respect to first-line therapy for anxiety disorders – antidepressants from the SSRI group. In a number of studies, it was shown that by not fully established mechanisms most representatives of this class of antidepressants (first of all, fluoxetine, fluvoxamine and paroxetine) can increase the concentration of allopregnanolone and some other neurosteroid in the corticolimbic zones of the brain. As a result, the anti-anxiety effect is at least partially developed not due to modulation of serotonin receptors, but due to neurosteroid-mediated activation of GABA receptors (Rupprecht et al. 2010).

Finally, altered neurosteroid levels may be one of the most likely explanations for women's increased propensity for depressive disorders in general, and for postpartum depression in particular. It has been shown experimentally that a significant increase in peripheral blood progesterone (during pregnancy or the follicular phase of the menstrual cycle) leads to a compensatory decrease in the sensitivity of GABA receptors to neurosteroid (by reducing the expression of δ -subunits). A subsequent decrease in the neurosteroid level against the background of GABA_A receptor activity decrease (during the luteal phase or after delivery) leads to the formation of affective symptoms (Brickley and Mody 2012). Currently, postpartum depression is the only reported indication for the use of Brexanolone (an artificially synthesized allopregnanolone). In addition to allopregnanolone, dehydroepiandrosterone, its sulfated form, and some others have also been shown to have antidepressant effects (van Broekhoven and Verkes 2003).

Some neurosteroids can act as allosteric modulators of NMDA receptors. Ligand-dependent, or rather co-controlled, ionotropic glutamate receptors are divided into subgroups according to their pharmacological properties: GluA (binds AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolpropionic acid), GluK (binds kainate), GluN (binds NMDA, N-methyl-D-aspartate) and GluD (binds d-serine) receptors. NMDA receptors are heterotetrameric ionotropic receptors consisting of two GluN1 subunits in combination with two GluN2 and/or GluN3 subunits (Vyklícky et al. 2014). NMDA receptors play a key role in the regulation of cognitive functions. NMDA receptor antagonism can occur through three pathways: competitive inhibition, blockade of ion channels, and noncompetitive inhibition through specific modulation sites (Vyklícky et al. 2014). Modulation of NMDA receptor activity can be either positive or negative. Positive modulators increase the affinity of the NMDA receptors agonist. Some neurosteroids, such as pregnenolone sulfate, are known to potentiate GluN2A and GluN2B-containing NMDA receptors, increasing the ability of the receptor to open the ion channel through phosphorylation (Vyklícky et al. 2014). However, the recent studies demonstrated that neurosteroids can also produce an inhibitory effect on this type of receptor. Pregnenolone sulfate is able to reduce the ability to open ion channels by a voltage-

independent mechanism. However, in this way, the inhibitory effect is produced only on previously activated (open) channels. The effect is less pronounced in GluN2A and GluN2B-containing receptors than in GluN2C and GluN2D-containing receptors (Adamusová et al. 2013). Apparently, the duality of the **pregnenolone sulfate** effect is explained by the different composition of the receptor subunits. The issue remains unresolved as the search for binding sites for neurosteroid inhibitors continues. **DHEA** can prevent NMDA-induced neurotoxicity to some extent, as well as increase the flow of Ca^{2+} ions into the cell through NMDA receptors (Li et al. 2009).

There is some experimental evidence for antipsychotic effects of some neurosteroids. In particular, intracerebral administration of **ALLO** to laboratory animals prevents the further appearance of motor agitation and other equivalents of psychosis after administration of high doses of amphetamines (Flood et al. 1992). This effect is probably related to the agonist effect of some neurosteroids on sigma-1 receptors, which can block dopamine release via NMDA receptors (which is consistent with the high efficacy of the sigma-1 receptor agonist **fluvoxamine** in psychotic depression, as well as with the presence of propsychotic effects when high doses of NMDA-receptor antagonists, such as ketamine, are taken) (Pabba and Sibille 2015).

Despite the fact that schizophrenia is not conceptualized as a classical neurodegenerative condition, a number of studies have shown the death of certain portions of neurons, mainly in the hippocampus (Cannon 2015). In this connection, the ability of a number of neurosteroid compounds to exert neuroprotective effect is of great interest. It is believed that neuroprotective effect of neurosteroids can be explained by three mechanisms – blocking of NMDA-receptors, stimulation of GABA_A -receptors, and modulation of polyunsaturated fatty acids metabolism. Moreover, many neurosteroids, according to experimental data, are also capable of enhancing neurogenesis and improving cognitive function through a variety of mechanisms, including action on NMDA receptors.

Presumably, sigma-1 receptors, along with NMDA receptors, affect neurocognitive functions. The administration of sigma-1 receptor agonists resulted in the increase in the GluN2A and GluN2B NMDA receptor subunits expression in the rat hippocampus (Pabba et al. 2014). Moreover, activation of sigma-1 receptor chaperones increased the of NMDA receptors presentation on the cell surface by stimulating the interaction between GluN2 subunits (Pabba et al. 2014). Sigma-1 receptors are involved in the transport and metabolism of ER lipids, the restoration of the lipid raft of the plasma membrane. Sigma-1 receptors are located in lipid raft-like microdomains of the endoplasmic reticulum membrane (Hayashi and Su 2010; Zhemkov et al. 2021). Sigma-1 receptors can modulate the transport of **cholesterol** into mitochondria and thereby regulate the processes of steroidogenesis. The

hypothesis is supported by reduced **pregnenolone** levels in the mice with sigma-1 receptor gene knockout (Marriott et al. 2012). In addition, sigma-1 receptors are involved in many cellular mechanisms: the release of neurotransmitters, the inositol phosphate system, inflammation, synaptogenesis, neuroplasticity, etc. Neuroplasticity is an important process in neuropsychiatric diseases. **Pregnenolone** and **DHEA** may produce beneficial effects in some neuropsychiatric disorders as sigma-1 receptor agonists. The studies demonstrated that the sulfated form of dehydroepiandrosterone can attenuate phencyclidine-induced cognitive loss in mice (Hashimoto 2015), whereas progesterone, like testosterone, inhibits sigma-1.

First of all, the properties of sigma-1 receptor agonists were revealed in **pregnenolone**, **DHEA**, and their metabolites, which makes them some of the most probable endogenous ligands of this receptor subtype (Monnet and Maurice 2006). According to the existing data, activation of sigma-1 receptors leads to a number of favorable effects, among which an anxiolytic effect is traditionally mentioned. The realization of the anxiolytic effect of neurosteroids through sigma-1 receptors has been proved in several studies on animal models. Of greatest interest is the work by Noda et al (2000), who showed the ability of sulfated forms of **pregnenolone** and **DHEA** to block evoked fear conditioning reactions in mice, and the introduction of the selective sigma-1 receptor antagonist NE-100 significantly reduced the effectiveness of neurosteroids.

Influence on this type of receptors may be responsible not only for anxiolytic but also for antidepressant effects. Apparently, the antidepressant effect of sigma receptor stimulation may be related to the increased release of noradrenaline and dopamine, as well as to the indirect modulation of NMDA-receptors (Bergeron et al. 1996).

Conclusion

Although the discovery and study of neurosteroids have been relatively recent, there is now a common understanding of the role of these substances, as well as their significant impact on the human psyche, in scientific community. Nevertheless, now many issues still require further research, and the data are somewhat controversial. A better understanding of the neurosteroidogenic pathways, as well as the interaction between neurosteroids, GABA_A -, NMDA- and sigma-1 receptors, will shed light on neurobiological processes, as well as open up new perspectives in the mental disorders treatment.

Conflict of interests

The authors declare no conflict of interests.

References

- Adamusová E, Cais O, Vyklický V, Kudová E, Chodounská H, Horák M, Vyklický L Jr (2013) Pregnenolone sulfate activates NMDA receptor channels. *Physiological Research* 62(6): 731–736. <https://doi.org/10.33549/physiolres.932558> [PubMed]
- Banks WA (2012) Brain meets body: the blood-brain barrier as an endocrine interface. *Endocrinology* 153(9): 4111–4119. <https://doi.org/10.1210/en.2012-1435> [PubMed] [PMC]
- Bergeron R, de Montigny C, Debonnel G (1996) Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. *The Journal of Neuroscience* 16(3): 1193–1202. <https://doi.org/10.1523/JNEUROSCI.16-03-01193.1996> [PubMed] [PMC]
- Brickley SG, Mody I (2012) Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. *Neuron* 73(1): 23–34. <https://doi.org/10.1016/j.neuron.2011.12.012> [PubMed] [PMC]
- Calderon-Dominguez M, Gil G, Medina MA, Pandak WM, Rodríguez-Agudo D (2014) The StarD4 subfamily of steroidogenic acute regulatory-related lipid transfer (START) domain proteins: new players in cholesterol metabolism. *The International Journal of Biochemistry & Cell Biology* 49: 64–68. <https://doi.org/10.1016/j.biocel.2014.01.002> [PubMed] [PMC]
- Cannon TD (2015) How schizophrenia develops: cognitive and brain mechanisms underlying onset of psychosis. *Trends in Cognitive Sciences* 19(12): 744–756. <https://doi.org/10.1016/j.tics.2015.09.009> [PubMed] [PMC]
- Compagnone NA, Mellon SH (2000) Neurosteroids: biosynthesis and function of these novel neuromodulators. *Frontiers Neuroendocrinology* 1(1): 1–56. <https://doi.org/10.1006/frne.1999.0188> [PubMed]
- Corpéchet C, Robel P, Axelson M, Sjövall J, Baulieu EE (1981) Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. *Proceedings of the National Academy of Sciences of the United States of America* 78(8): 4704–4707. <https://doi.org/10.1073/pnas.78.8.4704> [PubMed]
- Costa E, Cheney DL, Grayson DR, Korneyev A, Longone P, Pani L, Romeo E, Zivkovich E, Guidotti A (1994) Pharmacology of neurosteroid biosynthesis. Role of the mitochondrial DBI receptor (MDR) complex. *Annals of the New York Academy of Sciences* 746: 223–242. <https://doi.org/10.1111/j.1749-6632.1994.tb39240.x> [PubMed]
- Diotel N, Charlier TD, Lefebvre d'Helencourt C, Couret D, Trudeau VL, Nicolau JC, Meilhac O, Kah O, Pellegrini E (2018) Steroid transport, local synthesis, and signaling within the brain: roles in neurogenesis, neuroprotection, and sexual behaviors. *Frontiers in Neuroscience* 12: 84. <https://doi.org/10.3389/fnins.2018.00084> [PubMed] [PMC]
- Do Rego JL, Seong JY, Burel D, Leprince J, Vaudry D, Luthé V, Tonon MC, Tsutsui K, Pelletier G, Vaudry H (2012) Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides. *Frontiers in Endocrinology* 3: 4. <https://doi.org/10.3389/fendo.2012.00004> [PubMed] [PMC]
- Elustondo P, Martin LA, Karten B (2017) Mitochondrial cholesterol import. *Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids* 1862(1): 90–101. <https://doi.org/10.1016/j.bbalip.2016.08.012> [PubMed]
- Flood JF, Morley JE, Roberts E (1992) Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. *Proceedings of the National Academy of Sciences of the United States of America* 89(5): 1567–1571. <https://doi.org/10.1073/pnas.89.5.1567> [PubMed] [PMC]
- Hashimoto K (2015) Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. *Journal of Pharmacological Science* 127(1): 6–9. <https://doi.org/10.1016/j.jphs.2014.11.010> [PubMed]
- Hayashi T, Su TP (2010) Cholesterol at the endoplasmic reticulum: roles of the sigma-1 receptor chaperone and implications thereof in human diseases. *Sub-Cellular Biochemistry* 51: 381–398. https://doi.org/10.1007/978-90-481-8622-8_13 [PubMed] [PMC]
- Joshi S, Kapur J (2019) Neurosteroid regulation of GABAA receptors: A role in catamenial epilepsy. *Brain Research* 1703: 31–40. <https://doi.org/10.1016/j.brainres.2018.02.031> [PubMed] [PMC]
- Kalinina TS, Shimshir AA, Kudriashov NV, Voronina TA, Seredenin SB (2014) Neurosteroidogenesis and exploratory responses in rodents. *Experimental and Clinical Pharmacology [Eksperimental'naia i Klinicheskaiia Farmakologiya]* 77(2): 3–7. <https://pubmed.ncbi.nlm.nih.gov/24791332/> [PubMed] [in Russian]
- Khvostova EP, Pustyl'nyak VO, Korbut AI, Otpuschennikov AA, Gulyaeva LF, Krylova IN (2012) Modern approach to molecular characterization of prostate tumors. *Acta Biomedica Scientifica* 3(1): 83–88. [in Russian]
- Kraemer FB, Shen WJ, Azhar S (2017) SNAREs and cholesterol movement for steroidogenesis. *Molecular and Cellular Endocrinology* 441: 17–21. <https://doi.org/10.1016/j.mce.2016.07.034> [PubMed] [PMC]
- Lambert J, Belleli D, Hill-Venning C, Peters J (1995) Neurosteroids and GABA_A receptor function. *Trends in Pharmacological Sciences* 16(9): 295–303. [https://doi.org/10.1016/S0165-6147\(00\)89058-6](https://doi.org/10.1016/S0165-6147(00)89058-6) [PubMed]
- Larsen MC, Lee J, Jorgensen JS, Jefcoate CR (2020) STARD1 functions in mitochondrial cholesterol metabolism and nascent HDL formation. Gene expression and molecular mRNA imaging show novel splicing and a 1:1 mitochondrial association. *Frontiers in Endocrinology* 11: 559674. <https://doi.org/10.3389/fendo.2020.559674> [PubMed] [PMC]
- Li Z, Cui S, Zhang Z, Zhou R, Ge Y, Sokabe M, Chen L (2009) DHEA-neuroprotection and –neurotoxicity after transient cerebral ischemia in rats. *Journal of Cerebral Blood Flow and Metabolism* 29(2): 287–296. <https://doi.org/10.1038/jcbfm.2008.118> [PubMed]
- Longone P, di Michele F, D'Agati E, Romeo E, Pasini A, Rupprecht R (2011) Neurosteroids as neuromodulators in the treatment of anxiety disorders. *Frontiers in Endocrinology* 2: 55. <https://doi.org/10.3389/fendo.2011.00055> [PubMed] [PMC]
- Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 232(4753): 1004–1007. <https://doi.org/10.1126/science.2422758> [PubMed]
- Marriott KS, Prasad M, Thapliyal V, Bose HS (2012) σ -1 receptor at the mitochondrial-associated endoplasmic reticulum membrane is responsible for mitochondrial metabolic regulation. *The Journal of Pharmacology and Experimental Therapeutics* 343(3): 578–586. <https://doi.org/10.1124/jpet.112.198168> [PubMed] [PMC]
- McNeela AM, Bernick C, Hines RM, Hines DJ (2018) TSPO regulation in reactive gliotic diseases. *Journal of Neuroscience Research* 96(6): 978–988. <https://doi.org/10.1002/jnr.24212> [PubMed]

- Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG, Sage JR, Fanselow MS, Guidotti A, Spigelman I, Li Z, DeLorey TM, Olsen RW, Homanics GE (1999) Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. *Proceedings of the National Academy of Sciences of the United States of America* 96(22): 12905–12910. <https://doi.org/10.1073/pnas.96.22.12905> [PubMed] [PMC]
- Monnet F, Maurice T (2006) The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. *Journal of Pharmacological Sciences* 100(2): 93–118. <https://doi.org/10.1254/jphs.cr0050032> [PubMed]
- Noda Y, Kamei H, Kamei Y, Nagai T, Nishida M, Nabeshima T (2000) Neurosteroids ameliorate conditioned fear stress: an association with sigma receptors. *Neuropsychopharmacology* 23(3): 276–284. [https://doi.org/10.1016/S0893-133X\(00\)00103-2](https://doi.org/10.1016/S0893-133X(00)00103-2) [PubMed]
- Pabba M, Sibille E (2015) Sigma-1 and N-methyl-d-aspartate receptors: a partnership with beneficial outcomes. *Molecular Neuropsychiatry* 1(1): 47–51. <https://doi.org/10.1159/000376549> [PubMed] [PMC]
- Pabba M, Wong AY, Ahlskog N, Hristova E, Biscaro D, Nassrallah W, Ngsee JK, Snyder M, Beique JC, Bergeron R (2014) NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. *The Journal of Neuroscience* 34(34): 11325–11338. <https://doi.org/10.1523/JNEUROSCI.0458-14.2014> [PubMed] [PMC]
- Paul SM, Purdy RH (1992) Neuroactive steroids. *FASEB Journal* 6(6): 2311–2322. <https://doi.org/10.1096/fasebj.6.6.1347506> [PubMed]
- Porcello DM, Huntsman MM, Mihalek RM, Homanics GE, Huguenard JR (2003) Intact synaptic GABAergic inhibition and altered neurosteroid modulation of thalamic relay neurons in mice lacking delta subunit. *Journal of Neurophysiology* 89(3): 1378–1386. <https://doi.org/10.1152/jn.00899.2002> [PubMed]
- Rodriguez-Agudo D, Ren S, Hylemon PB, Montañez R, Redford K, Natarajan R, Medina MA, Gil G, Pandak WM (2006) Localization of StarD5 cholesterol binding protein. *Journal of Lipid Research* 47(6): 1168–1175. <https://doi.org/10.1194/jlr.M500447-JLR200> [PubMed]
- Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. *Nature Reviews. Drug Discovery* 9(12): 971–988. <https://doi.org/10.1038/nrd3295> [PubMed]
- Salman ED, Faye-Petersen O, Falany CN (2011) Hydroxysteroid sulfotransferase 2B1b expression and localization in normal human brain. *Hormone Molecular Biology and Clinical Investigation* 8(1): 445–454. <https://doi.org/10.1515/HMBCL.2011.117> [PubMed] [PMC]
- Schumacher M, Robel P, Baulieu E-E (2009) Neurosteroids. In: Squire LR (Ed.) *Encyclopedia of Neuroscience*, volume 1. Academic Press, Oxford, pp. 1015–1020.
- Shu HJ, Eisenman LN, Jinadasa D, Covey DF, Zorumski CF, Mennerick S (2004) Slow actions of neuroactive steroids at GABAA receptors. *The Journal of Neuroscience* 24(30): 6667–6675. <https://doi.org/10.1523/JNEUROSCI.1399-04.2004> [PubMed] [PMC]
- Sigel E (2002) Mapping of the benzodiazepine recognition site on GABA(A) receptors. *Current Topics in Medicinal Chemistry* 2(8): 833–839. <https://doi.org/10.2174/1568026023393444> [PubMed]
- Stell BM, Brickley SG, Tang CY, Farrant M, Mody I (2003) Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors. *Proceedings of the National Academy of Sciences of the United States of America* 100(24): 14439–14444. <https://doi.org/10.1073/pnas.2435457100> [PubMed] [PMC]
- Sugawara Y, Cheng WW, Bracamontes JR, Chen ZW, Wang L, Germann AL, Pierce SR, Senneff TC, Krishnan K, Reichert DE, Covey DF, Akk G, Evers AS (2020) Site-specific effects of neurosteroids on GABAA receptor activation and desensitization. *Elife* 9: e55331. <https://doi.org/10.7554/eLife.55331> [PubMed] [PMC]
- van Broekhoven F, Verkes RJ (2003) Neurosteroids in depression: a review. *Psychopharmacology* 165(2): 97–110. <https://doi.org/10.1007/s00213-002-1257-1> [PubMed]
- Vyklicky V, Korinek M, Smejkalova T, Balik A, Krausova B, Kaniakova M, Lichnerova K, Cerny J, Krusek J, Dittert I, Horak M, Vyklicky L (2014) Structure, function, and pharmacology of NMDA receptor channels. *Physiological Research* 63(Suppl 1): S191–S203. <https://doi.org/10.33549/physiolres.932678> [PubMed]
- Wang M (2011) Neurosteroids and GABA-A receptor function. *Frontiers in Endocrinology* 2: 44. <https://doi.org/10.3389/fendo.2011.00044> [PubMed] [PMC]
- Wang MD (2008) Neurosteroid: Molecular Mechanisms of Action on the GABAA Receptor. In: Ritsner MS, Weizman A (Eds) *Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders*. Springer, Dordrecht, 564 p. <https://doi.org/10.1007/978-1-4020-6854-6>
- Witt KA, Sandoval KE (2014) Steroids and the blood-brain barrier: therapeutic implications. *Advances in Pharmacology* 71: 361–390. <https://doi.org/10.1016/bs.apha.2014.06.018> [PubMed]
- Zhemkov V, Liou J, Bezprozvanny I (2021) Sigma 1 receptor, cholesterol and endoplasmic reticulum contact sites. *Contact* 4: 10.1177/25152564211026505. <https://doi.org/10.1177/25152564211026505>

Author contributions

- **Sakeena P. Bairamova**, Lab. Assistant of The Laboratory of Molecular Genetics, Department of Fundamental and Applied Neurobiology, e-mail: bairamova23s@gmail.com, **ORCID ID** <https://orcid.org/0000-0002-8099-2091> (synthesis of literature data, writing the article).
- **Dmitry S. Petelin**, PhD in Medicine, Assistant Professor at The Department of Psychiatry and Psychosomatics, e-mail: petelinhome1@yandex.ru, **ORCID ID** <https://orcid.org/0000-0002-2228-6316> (synthesis of literature data, writing the article).

- **Roman V. Akhapiin**, Dr Habilit. in Medicine, Deputy Director for Research, e-mail: 4ahapkin@gmail.com, **ORCID ID** <https://orcid.org/0000-0002-7045-0547> (development of the idea of the review paper, editing the manuscript).
- **Nikita V. Kudryashov**, PhD in Biology, Assistant Professor at The Department of Pharmacology, e-mail: kudryashov_n_v@staff.sechenov.ru, **ORCID ID** <https://orcid.org/0000-0002-1819-1867> (development of the idea of the manuscript, editing the manuscript).
- **Olga Yu. Sorokina**, PhD in Medicine, Head of Psychotherapy Department, e-mail: sorokina_o_yu@staff.sechenov.ru, **ORCID ID** <https://orcid.org/0000-0001-8863-8241> (search and analysis of literature).
- **Sergey A. Semin**, Psychiatrist at “Spaseniye” Psychiatric Hospital, e-mail: semockin171@mail.ru, **ORCID ID** <https://orcid.org/0000-0002-0061-1798> (search and analysis of literature).
- **Veronika Panfilova**, Undergraduate Student of The Sechenov First Moscow State Medical University, e-mail: verapanfilovaaa@gmail.com, **ORCID ID** <https://orcid.org/0000-0002-0890-9185> (search and analysis of literature).
- **Beatrice A. Volel**, Grand PhD in Medicine, Director of N.V. Sklifosovsky Institute of Clinical Medicine, e-mail: beatrice.volel@gmail.com, **ORCID ID** <https://orcid.org/0000-0003-1667-5355> (general supervision of writing the article, editing the final manuscript).